MGH study finds herceptin has additional antitumor qualities

Scientists at Massachusetts General Hospital (MGH) have discovered powerful anti-angiogenic properties in herceptin, a monoclonal antibody used to fight certain forms of breast cancer. Herceptin is known to block the cell receptor HER2 on breast cancer cells and is used to treat women whose tumors produce extra copies of HER2, a more aggressive form of cancer. The new data show that herceptin also targets multiple factors secreted by cancer cells which maintain the tumor's blood supply. In the March 21 issue of Nature, researchers from the MGH Department of Radiation Oncology show that herceptin can reduce the diameter and volume of tumor blood vessels, slow tumor growth, and prolong survival in animal models of cancer.

"The beauty of this molecule is that it has multiple anti-angiogenic effects and so it acts like a cocktail of angiogenesis-blocking drugs," says Rakesh Jain, PhD, director of the Steele Laboratory for Tumor Biology, the report's senior author. Scientists and physicians have been trying for years to block a tumor's ability to secrete factors that create new blood vessels and allow cancer cells to gain access to fresh supplies of blood and oxygen. However, when one of these angiogenic factors is successfully blocked, the cancer cells can adapt and secrete other factors. Jain and his team have found that herceptin can effectively target at least five factors, thereby thwarting a number of the cancer cells' tactics.

The MGH research includes clues that the host -- the body in which a tumor grows -- also plays a role in herceptin's effects. Following herceptin treatments, tumor cells cultured in the laboratory expressed more of certain angiogenic factors and less of others compared with tumors treated in mice. "This shows that we need to understand the host better," says Jain. "We used to think of a tumor as a big bag of cancer cells separate from the host, but now we know that host cells are active participants in cancer pro

Contact: Sue McGreevey
Massachusetts General Hospital

Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. UMaine study looks at infants and chronic nighttime crying
3. Chronic pain treatments more effective when taken together, new study shows
4. UNC study: Most N.C. family practitioners engage in unrecognized community service
5. New study in Nature demonstrates protection against cell death during heart attack
6. UCSF study offers insight into human circadian rhythms
7. International breast cancer prevention study launches in the United States and Canada
8. UW study shows blacks and Latinos are more satisfied with physicians of the same race
9. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
10. Advertising by academic medical centers may risk eroding public trust, says study
11. Fat may promote inflammation, new study suggests

Post Your Comments:

(Date:4/18/2019)... , ... April 18, 2019 , ... She went from ... pair of eyeglasses, said her mother, Cheryl Reilly. Those “goofy tests,” performed by ... Mikayla Reilly, then 12 years old, had such narrow range of visual awareness, she ...
(Date:4/18/2019)... ... April 18, 2019 , ... As cannabis ... Cannabis Industry Report . The study—which considers consumers’ perceptions of, attitudes about, and ... manufacturing, offering insight into what kinds of products consumers want to see. , ...
(Date:4/17/2019)... ATLANTA (PRWEB) , ... April 17, 2019 , ... Kadan ... nearly 35 years, announced today that it has received both the 2019 Best of ... Pulse. These awards are granted only to the top-ranking home care providers, based on ...
(Date:4/17/2019)... SAN DIEGO (PRWEB) , ... April 17, 2019 ... ... supplement created to help reduce hangover symptoms. This California-made supplement was designed ... productive routines. It is now available for purchase via GotPurpleTree.com and ...
(Date:4/17/2019)... , ... April 17, 2019 , ... ... on advances in revolutionary diagnostic technologies. This episode is scheduled to air 3Q ... this segment, Innovations will focus on Credo Biomedical Pte. Ltd. (Credo Biomedical), a ...
Breaking Medicine News(10 mins):
(Date:4/17/2019)... ... April 17, 2019 , ... Stealth ... mitochondrial dysfunction, announced yesterday at the 2019 Muscular Dystrophy Association (MDA) Clinical ... (OLE) clinical trial evaluating efficacy of elamipretide, an investigational product that targets ...
(Date:4/17/2019)... ... April 17, 2019 , ... The Job Research Foundation has ... into the causes of and treatments for Job Syndrome. , The Foundation awarded ... place around the globe in three countries, and on three continents. The recipients are: ...
(Date:4/17/2019)... ... April 17, 2019 , ... Kennywood is making a commitment ... spectrum, have an amazing experience. As part of this commitment, the amusement park ... Board of Credentialing and Continuing Education Standards (IBCCES) to organizations who have completed ...
Breaking Medicine Technology:
Cached News: